Payment overview · 2025
General Payments
$91.42
4 reported records · 4 companies
Healthcare provider profile · identity verified
Nathaniel Michael Farden, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · OSWEGO, NY · NPI 1144880964
Verified facts
What the public records show
CMS Open Payments records show Nathaniel Michael Farden, NP received $91.42 in general payments during 2025 across 4 reported records.
Insulet Corporation accounted for 44.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $40.80 | 44.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.31 | 22.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.22 | 16.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.09 | 16.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $91.42 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $40.80 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 203 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
203 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 426 | 69 |
| Atorvastatin Calcium | Atorvastatin Calcium | 415 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 296 | 80 |
| Omeprazole | Omeprazole | 291 | 63 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 253 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 241 | 47 |
| Trazodone Hcl | Trazodone Hcl | 228 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 214 | 40 |
| Lisinopril | Lisinopril | 213 | 42 |
| Famotidine | Famotidine | 209 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 203 | 41 |
| Losartan Potassium | Losartan Potassium | 189 | 45 |
| Baclofen | Baclofen | 157 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 147 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 25 |
| Meloxicam | Meloxicam | 119 | 29 |
| Metformin Hcl | Metformin Hcl | 118 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 116 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 115 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 114 | 37 |
| Eliquis | Apixaban | 112 | 17 |
| Sertraline Hcl | Sertraline Hcl | 105 | 23 |
| Furosemide | Furosemide | 103 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 47 |
| Tramadol Hcl | Tramadol Hcl | 99 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 17 |
| Montelukast Sodium | Montelukast Sodium | 93 | 18 |
| Jardiance | Empagliflozin | 92 | 19 |
| Buspirone Hcl | Buspirone Hcl | 89 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 84 | 12 |
| Xarelto | Rivaroxaban | 83 | 13 |
| Prednisone | Prednisone | 77 | 38 |
| Clonazepam | Clonazepam | 75 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 17 |
| Azelastine Hcl | Azelastine Hcl | 73 | 37 |
| Potassium Chloride | Potassium Chloride | 70 | 13 |
| Torsemide | Torsemide | 67 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 11 |
| Simvastatin | Simvastatin | 65 | suppressed |
| Allopurinol | Allopurinol | 64 | suppressed |
| Chlorthalidone | Chlorthalidone | 64 | 15 |
| Mirtazapine | Mirtazapine | 63 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 59 | suppressed |
| Carvedilol | Carvedilol | 56 | 12 |
| Aripiprazole | Aripiprazole | 54 | 16 |
| Pregabalin | Pregabalin | 54 | 11 |
| Topiramate | Topiramate | 54 | suppressed |
| Trulicity | Dulaglutide | 51 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 50 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 47 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 46 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 46 | 12 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 44 | 13 |
| Ozempic | Semaglutide | 43 | suppressed |
| Alprazolam | Alprazolam | 42 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | suppressed |
| Glipizide | Glipizide | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Spironolactone | Spironolactone | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Cephalexin | Cephalexin | 35 | 25 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 34 | 14 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Naproxen | Naproxen | 34 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Nystatin | Nystatin | 33 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | 11 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Azithromycin | Azithromycin | 24 | 20 |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 13 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Oxycontin | Oxycodone Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Atenolol | Atenolol | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | 11 |
| Betamethasone Valerate | Betamethasone Valerate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 13 |
| Glipizide Er | Glipizide | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Aristada | Aripiprazole Lauroxil | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Perseris | Risperidone | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Mupirocin | Mupirocin Calcium | 11 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $91.42 · 4 records | Insulet Corporation | AIRSUPRA, Omnipod, Ozempic, Rybelsus, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error